Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: Results, practical issues, safety,and future perspectives

Inflammatory Bowel Diseases

Volumn 15, Issue 7, 2009, Pages 1049-1054

  Ruuska, Tarja ^a   Wewer, V ^b   Lindgren, F ^c   Malmborg, P ^c   Lindquist, M ^d   Marthinsen, L ^e   Browaldh, L ^f   Casswall, T ^c   Kalliomaki M ^g   Gronlund J ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b HVIDOVRE HOSPITAL   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e Halmstad Central Hospital   (Sweden)

^f SACHS CHILDREN S HOSPITAL   (Sweden)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Children; Crohn's disease; Granulocyte monocyte adsorption; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; HEMOGLOBIN; HEPARIN; INFLIXIMAB; PARACETAMOL; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ALBUMIN BLOOD LEVEL; APHERESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRANULOCYTE MONOCYTE ADSORPTIVE APHERESIS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; PATIENT SAFETY; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; SCORING SYSTEM; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT INDICATION; ULCERATIVE COLITIS; DRUG RESISTANCE; FEMALE; GRANULOCYTE; IMMUNOLOGY; MALE; METHODOLOGY; MONOCYTE; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; REMISSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADRENAL CORTEX HORMONES; BLOOD COMPONENT REMOVAL; CHILD; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; CROHN DISEASE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MONOCYTES; PATIENT COMPLIANCE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 69449088730     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20859     Document Type: Article

References (29)

1. Langholz E, Munkholm P, Krasilnikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort. Scand J Gastroenterol. 1997;32:139-147.
2. Hildebrand H, Finkel Y, Grahnquist L, et al. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut. 2003;52:1432-1434.
3. Turunen P, Kolho KL, Auvinen A, et al. Incidence of inflammatory bowel disease in Finnish children 1987-2003. Inflamm Bowel Dis. 2006; 12:677-683.
4. Jakobsen C, Wewer V, Urne F, et al. Rising incidence in children of not only Crohn's disease, but also ulcerative colitis. A population based epidemiological study from Eastern Denmark. J Crohn Colitis. 2008;2: 152-157.
5. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am. 2003;32:967-995.
6. Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone health. Arch Dis Child. 2002;87:93-96.
7. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12.
8. Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in paediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298-301.
9. Hindorf U, Lindqvist M, Hildebrand A, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:331-342.
10. Kolho K-L, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007;96:128-130.
11. Kosh JR, Oliva-Henker M. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. J Pediatr Gastroenterol Nutr. 2007;44:165-167.
12. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001; 16:1-9.
13. Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35.
14. Tomomasa T, Kobayashi A, Kaneko H, et al. Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci. 2003;48:750-754.
15. Ikeda H, Ishimaru Y, Takayasu H, et al. Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr. 2006;43:592-596.
16. Ruuska T, Lähdeaho ML, Sutas Y, et al. Selective leucocyte apheresis in the treatment of paediatric ulcerative colitis. Scand J Gastroenterol. 2007;42:1390-1391.
17. de Carpi JV, Vilar P, Prieto G, Novo MDG, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorptive apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr. 2008;46:386-391.
18. McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Excp Immunol. 1991;86:486-493.
19. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:21-33.
20. Saniabadi AR, Hanai H, Takeuchi K, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48-59.
21. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994; 35:360-362.
22. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;57;331-338.
23. Turner D, Otley AR, Mack D, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41;416-421.
24. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58.
25. Bresci G, Parisi G, Mazzoni A, et al. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis. 2007;39:430-434.
26. Hanai H, Watanabe F, Yameda M, et al. Adsorbtive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44.
27. Ruuska T, Savilahti E, Maki M, et al. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr. 1994;19:175-180.
28. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118-1123.
29. Munkholm P. Crohn's disease - occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull. 1997;44:287-302.